Paragon Care Limited · ASX:PGC
Paragon Care — Investor Presentation (August 2026)
33 slides from Paragon Care's investor presentation, Aug 26, 2026
Slide 1: Annual Financial Results Year Ended 30 June 2026
Annual Financial Investor Presentation Results Year Ended 30 June 2026 • ParagonCare Limited - ASX PGC ParagonCare - FY26 Results
Slide 2: Acknowledgement of Country and Traditional Owners
Acknowledgement of Country and Traditional Owners ParagonCare acknowledges the Traditional Owners of the country in which our headquarters are located, in Australia. We recognise the continuing connection to lands, waters and communities and pay our respects to Aboriginal and Torres Strait Islander
Slide 3: Presenters
Carmen Riley Brendon Pentland Chief Executive Officer Chief Financial Officer Presenters ParagonCare - FY26 Results
Slide 4: FY26 Highlights
FY26 HIGHLIGHTS Revenue and Underlying Earnings Growth Amounts included throughout this document have not been subject to an audit or review by the external auditors of the Group. FY26 Underlying^ Revenue EBITDA ^ Net Profit After Tax ^ $3.7 billion $97.2 million $26.0 million Up +1.8% on pcp Up +2.
Slide 5: FY26 Financial Performance – Strategic Transformation
FY26 FINANCIAL PERFORMANCE – STRATEGIC TRANSFORMATION Completion of 3-2-1 Strategy $3.7 $26.0 $97.2 $23.7 billion million million million 2.5x Revenue Underlying NPAT1 Underlying EBITDA1 Cash balance Underlying Net Debt2 Up +1.8% on pcp Down (13.6%) on pcp Up +2.1% on pcp Up +16.5% on pcp Recap $3.7
Slide 6: Capital Allocation and Returns
CAPITAL ALLOCATION AND RETURNS Major capital allocation Investment in earnings accretive acquisitions $51.4 $31.6 $35.2 Capex investment in new Willawong DC, including Manhatton WMS and Automation million million million IT Capability investment Acquisitions Net Capex Interest Interest expenses alig
Slide 7: Sales Channel Highlights
SALES CHANNEL HIGHLIGHTS Wholesale Medical Technology Contract Logistics Clinical Manufacturing • Trusted independent healthcare wholesaler • Broaden ParagonCare Australia's portfolio and • Trusted healthcare supply chain partner for • IVD manufacturing, contract manufacturing, throughout Australia
Slide 8: Financial Performance
Financial Performance ParagonCare - FY26 Results
Slide 9: FY26 Financial Result
FY26 FINANCIAL RESULT Delivered revenue and underlying earnings growth Underlying Result - $m FY26 FY25 Var $ Var % Revenue Revenue 3,680.5 3,613.9 66.6 1.8% • Group revenue growth before normalisations (refer Revenue Bridge slide 14) up 1.8% v. pcp EBITDA 97.2 95.2 2.0 2.1% • Normalised revenue gro
Slide 10: FY26 Financial Result
FY26 FINANCIAL RESULT Delivered revenue and underlying earnings growth Expenses Underlying Result - $m FY26 FY25 Var $ Var % Revenue 3,680.5 3,613.9 66.6 1.8% • Operating costs were impacted by higher freight charges and offsite storage with the delay EBITDA 97.2 95.2 2.0 2.1% of the Brisbane DC, op
Slide 11: Statutory to Underlying Earnings Reconciliation FY26
STATUTORY TO UNDERLYING EARNINGS RECONCILIATION FY26 Delivering Underlying Earnings Growth Item FY26 EBITDA EBIT PBT NPAT Statutory 50.8 13.5 (21.7) (16.0) Adjusted for items identified as excluded from underlying earnings: Provision for Infinity debt, net of GST recovered1 34.9 34.9 34.9 24.4 Merge
Slide 12: FY26 Balance Sheet
FY26 BALANCE SHEET NWC discipline & controlled leverage support targeted M&A $m FY26 FY25+ Var $ Var % Net Working Capital Receivables 370.7 401.5 (30.8) (7.7%) • Receivables lower due to Infinity ECL and partly offset by acquisitions Inventory 342.1 282.5 59.6 21.1% • Inventory increase driven by a
Slide 13: FY26 Cash Flow
FY26 CASH FLOW Strong cash generation, disciplined debt-funded M&A $m FY26 FY25+ Var $ Var % Commentary Cash flows from operations 65.8 34.7 31.1 89.4% Operating Activities Net interest paid (34.4) (33.2) (1.2) 3.6% • Cash flows from operations $65.8 million, up 89.4% on pcp Tax paid (2.3) (15.0) 12
Slide 14: FY26 Revenue Bridge
FY26 REVENUE BRIDGE Strong normalised revenue growth Normalised Revenue Revenue Bridge • Group revenue growth, before normalisations (Infinity $3,700.0 $229.9 $3,680.5 Group sales, Ramsay exit and FX impact), was 1.8% v. pcp $3,613.9 $3,600.0 • Adjusted for normalisations, Group revenue growth was 6
Slide 15: FY26 EBITDA
FY26 EBITDA Normalised EBITDA growth well ahead of headline Underlying EBITDA EBITDA Bridge • Group EBITDA growth, before normalisations, was 2.1% v. $110.0 pcp $8.6 • Normalised Group EBITDA growth was 7.4% v. pcp after $105.0 ($3.8) adjusting for the impact of Infinity Group, FY26 acquisitions, $1
Slide 16: Australia and New Zealand
Australia and New Zealand ParagonCare - FY26 Results
Slide 17: Australia & New Zealand Segment Overview
AUSTRALIA & NEW ZEALAND SEGMENT OVERVIEW Normalised revenue growth despite Infinity Group & Ramsay exits Revenue $m FY26 FY25 Var $ Var % Normalised revenue growth despite challenges: Wholesale 2,825.4 2,979.0 (153.6) (5.2%) • Reported ANZ total revenue growth of 0.2% was pleasing despite the loss o
Slide 18: Australia & New Zealand Segment Overview
AUSTRALIA & NEW ZEALAND SEGMENT OVERVIEW Margin holds firm despite challenges Revenue $m FY26 FY25 Var $ Var % Margin improvement in three of four channels: Wholesale 2,825.4 2,979.0 (153.6) (5.2%) • ANZ segment margin held steady at 8.0% Medical Technology 168.9 169.7 (0.9) (0.5%) • Wholesale margi
Slide 19: Asia
Asia ParagonCare - FY26 Results
Slide 20: Asia Segment Overview
ASIA SEGMENT OVERVIEW Strong organic & acquisitive growth broadens the margin base Revenue $m FY26 FY25 Var $ Var % Margin $m FY26 FY25 Var $ Var % Medical Technology 160.1 101.3 58.8 58.0% Medical Technology 67.3 47.0 20.4 43.4% Asia Total Revenue 160.1 101.3 58.8 58.0% Asia Total Margin 67.3 47.0
Slide 21: Acquisitions
Acquisitions ParagonCare - FY26 Results
Slide 22: Acquisitions Overview
ACQUISITIONS OVERVIEW Completed acquisitions contribute to FY26 growth in line with Asia expansion strategy Haju Medical – acquired April 2026 AHP – acquired July 2025 Haju supplies a wide range of leading aesthetics brands in Indonesia and AHP was acquired to broaden PGC’s product offer and custome
Slide 23: Strategy and Outlook
Strategy and Outlook ParagonCare - FY26 Results
Slide 24: Strategic Overview
STRATEGIC OVERVIEW Making healthcare simpler, smarter and more accessible across Asia Pacific ParagonCare is a leading diversified healthcare distributor and manufacturer across Asia Pacific. We achieve this through a combination of customer focus, our extensive product range, knowledge-based soluti
Slide 25: FY27 Outlook
FY27 OUTLOOK One partner for the whole of healthcare Geographic & market expansion • Continue to grow our Asia regional presence • Leverage capability and market opportunities in acquired businesses • Expand aesthetics business in Australia and Asian territories • Strategic M&A opportunities Growth
Slide 26: Q&A
Q&A ParagonCare - FY26 Results
Slide 27: Appendix
Appendix ParagonCare - FY26 Results
Slide 28: Results by Half - Group
RESULTS BY HALF - GROUP First Half Second Half Full Year Underlying Result - $m FY26 FY25 Var % FY26 FY25 Var % FY26 FY25 Var % Revenue 1,904.9 1,850.4 2.9% 1,775.6 1,763.5 0.7% 3,680.5 3,613.9 1.8% EBITDA 49.0 47.5 3.2% 48.2 47.7 1.0% 97.2 95.2 2.1% Depreciation & Amortisation 15.3 15.3 - 11.9 7.8
Slide 29: Results by Half – Segment & Channel
RESULTS BY HALF – SEGMENT & CHANNEL First Half Second Half Full Year Revenue - $m FY26 FY25 Var % FY26 FY25 Var % FY26 FY25 Var % Wholesale 1,500.0 1,553.2 (3.4%) 1,325.4 1,425.8 (7.0%) 2,825.4 2,979.0 (5.2%) Medical Technology 86.0 68.8 25.1% 82.8 100.9 (17.9%) 168.9 169.7 (0.5%) Contract Logistics
Slide 30: Environment, Social, Governance
Environment, Social, Governance ParagonCare - FY26 Results
Slide 31: Sustainability Disclosures
SUSTAINABILITY DISCLOSURES ParagonCare has prepared its first climate-related report, establishing a foundation for future progress. The Group intends to progressively strengthen the monitoring of climate-related risks, considering emerging opportunities and integrate these considerations into strat
Slide 32: Disclaimer
DISCLAIMER This document has been prepared by Paragon Care Limited ACN 064 551 426 (ASX: PGC) (ParagonCare or the Company) (Presentation). The material in this Presentation contains general background information about ParagonCare and its current activities as at the date of this Presentation. The i
Slide 33: Thank you
Thank you ParagonCare - FY26 Results 33